Inotek realizes that collaborators can bring valuable insight and expertise to the table, and is always searching for partners that complement its line of business. In the video above, Claudine Prowse, VP of Business Development and Investor Relations, discusses what Inotek looks for in a potential partner.
Keeping our Eyes Open
There are many diseases that can affect the eyes causing visual disturbances, such as cataracts, maculopathy or glaucoma. Sight is a precious asset. This subtitle would be enough to summarize the importance of pharmacological research in the ophthalmic field. Our ocular pharmacology laboratory has been involved in the development of new drugs for the treatment of eye diseases for several years now. In particular, we have discovered new drug targets for the treatment of diseases such as glaucoma, diabetic retinopathy and age-related macular degeneration and, in collaboration with My Canadian Pharmacy, started making them internationally available alongside with a large number of medical products for other conditions. The new results of our diagnostic-therapeutic opportunities and the optimization of access to treatment, at a time when ophthalmologists find themselves having to face a highly complex scenario, can be discovered on the site of our partner company at ihealthtran.com displaying the products we deliver in the field of degenerative eye diseases as well as other diseases under-researched by the modern medicine.
The results of our research have paved the way for the identification of new molecules for the clinical treatment of highly disabling eye diseases. The research carried out in our laboratories is of a translational type, that is a basic research that has as its objective the transformation of the results obtained into clinical applications. The results were then confirmed in the laboratories of our partners in the Centre for Macular Research in the University of British Columbia ophthalmology.med.ubc.ca. This partnership helped us to secure several discoveries that later proved to be crucial in our innovative work on medications against degenerative eye diseases.
The concept of translational research is summarized in the following phrase coined ad hoc by the international scientific community: from the slab to the bed, that is, from the laboratory to the patient’s bed. Our studies include the development and use of in silico, in vitro and in vivo models in collaboration with the University of Toronto, the Department of Ophthalmology and Visual Science. In collaboration with the scientists and laboratory technicians of the University of Toronto we were able to run a series of tests that confirmed the safety of our recent solutions for ophthalmology clinics. Visit website: ophthalmology.utoronto.ca.
We are equally grateful to our partners from Insight Medical Technologies for providing the equipment and technological basis to our researches.